Serum C-reactive protein level in postsplenectomized thalassemic patients.

Area of Science:

• Hematology
• Immunology
• Biochemistry

Background:

• C-reactive protein (CRP) is a key marker for inflammation.
• Interleukin-6 (IL-6) is a primary driver of hepatic CRP synthesis.
• Elevated inflammatory markers, including IL-6, have been observed in postsplenectomized thalassemic patients.

Purpose of the Study:

• To quantify serum CRP concentrations in postsplenectomized beta-thalassemia patients (beta-thal/HbE postsplenec).
• To compare CRP levels in beta-thal/HbE postsplenec patients with other groups: non-splenectomized beta-thalassemia patients (beta-thal/HbE), postsplenectomized non-thalassemic patients (postsplenec), reactive thrombocytosis (RT), chronic myeloproliferative disorders (MPD), and healthy volunteers.

Main Methods:

• Serum CRP was measured using an automatic Behring Nephelometer.
• The study included 28 beta-thal/HbE postsplenec, 22 beta-thal/HbE, 12 postsplenec, 23 RT, 21 MPD, and 26 healthy adult volunteers.

Main Results:

• CRP levels were significantly higher in beta-thal/HbE postsplenec patients compared to beta-thal/HbE (4.1 vs. 1.6 mg/L) and normal volunteers (4.1 vs. 0.45 mg/L).
• CRP levels in beta-thal/HbE postsplenec patients were higher than in the postsplenec group (4.1 vs. 0.19 mg/L), but significantly lower than in RT patients (4.1 vs. 55.4 mg/L).
• No statistically significant difference in CRP was found between beta-thal/HbE postsplenec patients and MPD patients (4.1 vs. 17.1 mg/L). A trend towards increased CRP with higher platelet counts was noted in beta-thal/HbE postsplenec patients.

Conclusions:

• Postsplenectomy in beta-thalassemia patients is associated with elevated serum CRP levels.
• Platelet count and/or thrombopoiesis-regulating factors may influence high CRP levels in these patients, beyond just the inflammatory process.